Pharmacovigilance Risk Assessment Committee (PRAC) provides new testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine

Patients receiving iv or intraarterial fluorouracil, or capecitabine or tegafur (both prodrugs of FU), should be tested for lack of dihydropyrimidine dehydrogenase (DPD) before starting treatment-lack of DPD may lead to fluorouracil toxicity eg neutropenia, neurotoxicity.

SPS commentary:

Pre-treatment testing for flucytosine is not required, so that start of treatment with flucytosine is not delayed especially in those with severe fungal infections, including some forms of meningitis.


European Medicines Agency